The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer.
The guidance was considered for reassessment in January 2011 and it was concluded that NICE will not be updating this guidance at this stage. However, if you believe there is new evidence which should warrant a review of our guidance, please email email@example.com.
This procedure is used for early-stage bladder cancer, and may be used before or after surgery. Solutions of chemotherapeutic drugs are delivered into the bladder using a thin tube inserted through the urethra. At the same time, an antenna placed inside the bladder emits microwaves that heat up the bladder lining. The heating is intended to damage the cancer cells and enhance the effect of the chemotherapeutic drugs.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.